Flexion Therapeutics (FLXN) PT Set at $18.00 by Laidlaw

Share on StockTwits

Flexion Therapeutics (NASDAQ:FLXN) received a $18.00 price objective from stock analysts at Laidlaw in a research note issued on Thursday, TipRanks reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Laidlaw’s target price would indicate a potential upside of 71.27% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Wells Fargo & Co reiterated a “buy” rating and set a $26.00 price target on shares of Flexion Therapeutics in a report on Friday, December 28th. Zacks Investment Research upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Monday, December 24th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target (down previously from $42.00) on shares of Flexion Therapeutics in a report on Friday, January 4th. Northland Securities reiterated a “buy” rating and set a $20.00 price target on shares of Flexion Therapeutics in a report on Friday, March 1st. Finally, Raymond James reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $22.64.

Shares of NASDAQ FLXN traded down $0.49 during trading on Thursday, hitting $10.51. 826,480 shares of the company were exchanged, compared to its average volume of 798,515. Flexion Therapeutics has a 12-month low of $9.90 and a 12-month high of $29.10. The company has a quick ratio of 7.58, a current ratio of 7.78 and a debt-to-equity ratio of 1.35. The firm has a market cap of $417.92 million, a PE ratio of -2.34 and a beta of 1.68.

In other Flexion Therapeutics news, insider Michael D. Clayman acquired 4,046 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $12.36 per share, with a total value of $50,008.56. Following the transaction, the insider now owns 70,856 shares of the company’s stock, valued at $875,780.16. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.59% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its position in shares of Flexion Therapeutics by 4.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 16,668 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 772 shares during the last quarter. Carroll Financial Associates Inc. increased its position in shares of Flexion Therapeutics by 100.0% during the 4th quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 1,000 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Flexion Therapeutics by 2.7% during the 4th quarter. Macquarie Group Ltd. now owns 68,484 shares of the specialty pharmaceutical company’s stock worth $775,000 after purchasing an additional 1,781 shares during the last quarter. Advisor Group Inc. increased its position in shares of Flexion Therapeutics by 68.2% during the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 3,490 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Flexion Therapeutics by 2.1% during the 4th quarter. American Century Companies Inc. now owns 175,780 shares of the specialty pharmaceutical company’s stock worth $1,990,000 after purchasing an additional 3,666 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: Marijuana Stocks Investing Considerations

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Citizens Bank & Trust Co. Has $125,000 Position in SRC Energy Inc
First Citizens Bank & Trust Co. Has $125,000 Position in SRC Energy Inc
First Citizens Bank & Trust Co. Acquires New Stake in US Xpress Enterprises Inc
First Citizens Bank & Trust Co. Acquires New Stake in US Xpress Enterprises Inc
Cribstone Capital Management LLC Has $39,000 Position in Schlumberger Limited.
Cribstone Capital Management LLC Has $39,000 Position in Schlumberger Limited.
ResMed Inc.  Shares Sold by DNB Asset Management AS
ResMed Inc. Shares Sold by DNB Asset Management AS
DNB Asset Management AS Sells 3,632 Shares of Westrock Co
DNB Asset Management AS Sells 3,632 Shares of Westrock Co
DNB Asset Management AS Has $1.67 Million Stake in Arthur J Gallagher & Co
DNB Asset Management AS Has $1.67 Million Stake in Arthur J Gallagher & Co


© 2006-2019 Ticker Report